Juan José Lahuerta
0000-0002-3393-9570
Fundación Pethema
13 papers found
Refreshing results…
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma
Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches
Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma
Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma
Biological and clinical significance of dysplastic hematopoiesis in patients with newly-diagnosed multiple myeloma
Missing publications? Search for publications with a matching author name.